{
  "id": 3964123,
  "title": "Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?",
  "url": "https://urgent.news/2026/08/28/revolution-medicines-won-fda-approval-one-month-after-filing-analysts-3964123",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-28T11:07:01.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/08/28/revolution-medicines-won-fda-approval-one-month-after-filing-analysts-see-115-billion-in-peak-sales-is-the-stock-still-a-buy-after-skyrocketing-more-than-5x/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": null,
  "summary": "The biotech's Rasonque is already available for prescription.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?",
        "url": "https://urgent.news/2026/08/28/revolution-medicines-won-fda-approval-one-month-after-filing-analysts",
        "published": "2026-08-28T11:27:01.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}